| 000 | 01574 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516190331.0 | ||
| 264 | 0 | _c20140604 | |
| 008 | 201406s 0 0 eng d | ||
| 022 | _a1545-5017 | ||
| 024 | 7 |
_a10.1002/pbc.24899 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCorder, Amy | |
| 245 | 0 | 0 |
_aRetrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis. _h[electronic resource] |
| 260 |
_bPediatric blood & cancer _cJun 2014 |
||
| 300 |
_a1063-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aAntithrombin III _xadministration & dosage |
| 650 | 0 | 4 | _aCritical Illness |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEnoxaparin _xadministration & dosage |
| 650 | 0 | 4 | _aFactor Xa Inhibitors |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aThrombosis _xdrug therapy |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aHeld, Kristin | |
| 700 | 1 | _aOschman, Alexandra | |
| 773 | 0 |
_tPediatric blood & cancer _gvol. 61 _gno. 6 _gp. 1063-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/pbc.24899 _zAvailable from publisher's website |
| 999 |
_c23403151 _d23403151 |
||